A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

Clinical trial NCT01602224 · COMPLETED

Trial details

NCT number: NCT01602224
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2012-07-01
Primary completion: 2014-07-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.